(Reuters) -Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than ...

Novo, which became Europe’s most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as ...

Lilly has touted head-to-head data that suggests Zepbound may have superior weight loss capabilities to Wegovy in terms of ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the name-brand medicine. The company says it trying to stop them.

On Tuesday, Novo took an axe to its financial outlook in a surprise corporate update call where it replaced its CEO with an ...